Bayer's Twin Regulatory Push in Japan Sharpens the Pharma Growth Narrative
Published on 08/30/2026 at 11:13 | Editorial boerse-global.de
The spotlight has swung back to Bayer's pharmaceuticals division, where a pair of regulatory milestones in Japan is giving investors a fresh lens through which to view the German conglomerate's turnaround story. The developments arrive at a moment when the group's operational achievements are increasingly competing with—and, for now, overshadowing—the legal overhang that has dogged the stock for years.
At the heart of the momentum is Kerendia, the kidney and heart medication that continues to deliver blockbuster-style growth. Bayer has filed an application with Japan's PMDA to expand the drug's indication to include non-diabetic chronic kidney disease, backed by positive Phase-III data from the FIND-CKD study. If approved, the move would substantially widen the addressable patient population in one of the world's most important pharmaceutical markets.
The commercial trajectory of Kerendia is already telling its own story. The drug generated quarterly sales of €329 million in the second quarter of 2026, an 80 percent surge year-on-year. Management has reaffirmed its target of surpassing €1 billion in annual revenue from the medicine this year, and a green light from Japanese regulators would provide additional tailwind to that ambition.
Just as Bayer is expanding its risk assessment of patient populations to unlock new growth, workplace safety demands the same rigorous approach. Many employers underestimate dangerous gaps in their health and safety documentation that could leave them exposed. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace risks in a legally compliant way. Download the free Risk Assessment Toolkit
Oncology Portfolio Gains a New Arrow
Just days before the Kerendia filing, Bayer secured marketing approval in Japan for Hyrnuo, the brand name for Sevabertinib. The oncology treatment targets patients with HER2-mutated non-small cell lung cancer and has been cleared for use across all treatment lines. The approval adds a fresh weapon to Bayer's cancer portfolio and underscores the group's pivot toward specialized therapeutic areas where pricing power and clinical differentiation matter most.
The regulatory wins in Japan are strategically significant because they reinforce the narrative that Bayer's pharma pipeline is viable and commercially productive—a crucial counterweight to the persistent glyphosate litigation concerns that have historically dominated the investment debate. A medicine nearly doubling its sales within a year provides tangible evidence that the pharmaceutical engine can drive growth even as other parts of the business face structural headwinds.
Structural Moves in Agriculture
On the crop science side, Bayer has taken steps to reorganize its glyphosate operations. The entire US glyphosate business has been carved out into a newly established subsidiary, Ruvon LLC, based in St. Louis. The company describes the move as enhancing operational agility in the generics market environment—a pragmatic approach that separates the lower-margin business organizationally without fully divesting it.
The legal uncertainty surrounding glyphosate, however, remains a defining feature of the risk profile. Despite a favorable US Supreme Court ruling, Bayer has maintained provisions of €11.8 billion for the current year. That caution suggests management is not banking on a swift resolution to the litigation wave, even with recent judicial relief.
Financial Leadership Transition and Confirmed Guidance
The second-quarter results presentation also marked the official debut of Judith Hartmann as chief financial officer, succeeding Wolfgang Nickl. The leadership change at the finance helm coincides with Bayer confirming its annual guidance in the half-year report and reporting progress on strategic priorities—a combination that offers investors a measure of stability.
The share price has been reflecting the improving tone. Bayer closed Friday at €48.66, up 0.4 percent on the day and 1.4 percent higher on the week. The stock has gained 31 percent since the start of the year and trades roughly 18 percent above its 200-day moving average of €41.29, an indication of a firmly established medium-term uptrend. On a twelve-month view, the equity has appreciated 74 percent. The shares currently sit just above their 50-day average of €47.96, with the distance to the early-July 52-week high standing at approximately ten percent.
Managing regulatory risk is just as critical for your own business as it is for a multinational like Bayer. Many UK companies unknowingly breach the Health & Safety at Work Act 1974, leaving themselves exposed to costly fines and enforcement action. This free toolkit provides 9 ready-to-use tools, including risk assessments, checklists, and a director liability guide, to help you stay compliant and protect your workforce. Get the free Health & Safety at Work Act Toolkit
Key Dates on the Horizon
Investors have two significant dates to track. On September 2, Bayer hosts its Crop Science Investor Event 2026, where management is expected to detail the future structure and strategy of the agriculture division—a presentation that could shed light on how the Ruvon carve-out fits into the broader organizational design.
Then, on September 14, a Missouri court will review the framework of the multibillion-dollar glyphosate settlement. Until that hearing concludes, the interplay between pharmaceutical progress and legal risk is likely to remain the defining dynamic for the stock. For now, the operational narrative is carrying the day, but the legal calendar still casts a long shadow over the investment case.
